Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

Published:2020-11-18 Issue:3 Volume:184 Page:561-563
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Nettis E.¹,Fabbrocini G.²,Ortoncelli M.³,Pellacani G.⁴,Argenziano G.⁵,Di Leo E.⁶^ORCID,Patruno C.⁷,Stingeni L.⁸^ORCID,Foti C.⁹,Rongioletti F.¹⁰^ORCID,Macchia L.¹,Tavecchio S.¹¹¹²^ORCID,Napolitano M.¹³^ORCID,Ribero S.³^ORCID,Bonzano L.¹⁴^ORCID,Calabrese G.⁵^ORCID,Di Bona D.¹,Nisticò S.P.⁷,Hansel K.⁸,Romita P.⁹^ORCID,Piras V.¹⁰,Carbonara M.¹⁵,Detoraki A.¹⁶^ORCID,Ferrucci S.M.¹¹

Affiliation:

1. University of Bari ‐ Aldo Moro

2. University of Naples Federico II

3. University of Turin

4. University of Modena and Reggio Emilia

5. University of Campania

6. Unit of Internal Medicine‐"F. Miulli" Hospital Acquaviva delle Fonti

7. University Magna Graecia of Catanzaro

8. University of Perugia

9. Unit of Dermatology University of Bari

10. University of Cagliari

11. UOC Dermatologia Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico

12. Università degli Studi di Milano

13. University of Molise

14. AUSL Modena

15. National Institute of Statistics (ISTAT)

16. Azienda Ospedaliera Universitaria Federico II

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19577

Reference7 articles.

1. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

2. Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

3. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study

4. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

5. Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08

2. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China;Archives of Dermatological Research;2024-05-31

3. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience;Actas Dermo-Sifiliográficas;2024-02

4. [Artículo traducido]Eficacia y seguridad de dupilumab para el tratamiento de la dermatitis atópica grave en la práctica clínica: experiencia en un centro terciario;Actas Dermo-Sifiliográficas;2024-02

5. Considerations for managing elderly patients with atopic dermatitis;Expert Review of Clinical Immunology;2024-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3